bleeding-have been treated. Without training in this aspect of care (triage) the first casualty encountered may receive five star treatment while several others deteriorate because of simple airway obstruction. Although the training of mobile teams is obviously an essential part of the preparation for major incidents, it varies in quantity and quality across the country-as shown by a short report in this week's journal (p 748). 4 Considering the difficulties it is little short of miraculous that the doctors inexperienced in this type of care cope so well.
The increasing numbers ofimmediate care schemes and the extended role ofparamedics in the ambulance service give rise to optimism. Advanced trauma life support courses are now established and provide an excellent format for training and coordinating the medical and paramedical staff. 5 The most important criterion for inclusion in the mobile team is specialist training but if this has not been possible anaesthetists probably possess many of the skills necessary for on site care.
Local needs and logistics will affect the organisation of accident planning. With the emergence of trauma centres and the greater use of intervention vehicles and helicopters training may become more centralised. The resources necessary for every hospital to support and maintain a satisfactory mobile team are formidable, and disasters occur so rarely that maintaining a satisfactory level of motivation and skill is difficult. Mobile teams based on few large centres but with good communications and logistical support may be the way forward. D 
Radioiodine for hyperthyroidism
Perhaps the best option Thyrotoxicosis is common, affecting an estimated 2.7% of women in Britain.' The antithyroid drugs carbimazole and propylthiouracil effectively control thyrotoxicosis in the short term, rapidly relieving symptoms and reducing plasma concentration ofthyroid hormones. In Graves' disease (hyperthyroidism due to stimulating antibodies directed against the receptor for thyroid stimulating hormone), however, these drugs produce long term remission in only about half of cases depending on the length of treatment,2 although improved results have recently been reported when thyroxine was added to carbimazole. 3 In those patients with solitary toxic nodules or toxic multinodular goitre such drugs probably never produce long term remission. This failure of antithyroid drugs to cure thyrotoxicosis in the majority of patients, together with the need for repeated monitoring and adjustment of such treatment, means that most patients eventually need definitive treatment, the therapeutic options being partial thyroidectomy and radioiodine.
In Europe, the United States, and Japan thyrotoxicosis is now rarely considered an indication for partial thyroidectomy.4 This is because surgery is associated with greater short term morbidity, mortality, and cost than treatment with radioiodine. The operation carries the risks of recurrent laryngeal nerve palsy and hypoparathyroidism even in the best surgical hands. In addition, recurrent thyrotoxicosis occurs in about 10% of patients treated by partial thyroidectomy, and those with recurrent disease usually require radioiodine because a second operation is more hazardous than the first.
The main long term complication of both partial thyroidectomy and radioiodine is hypothyroidism, which occurs in up to 40% of patients 25 years after treatment.5 (The risks of hypothyroidism are similar after both forms of treatment.) The prevalence of hypothyroidism after radioiodine varies with the dose given, although attempts to identify factors in individual patients that might predict the cure of thyrotoxicosis and avoidance of thyroid failure have been unsuccessful. 6 Whether treating Graves' disease with radioiodine increases the risk or severity of ophthalmopathy remains controversial. Evidence from a large retrospective study that the type of antithyroid treatment does not affect the course of ophthalmopathy7 provides support for the recommendation that hyperthyroidism should be treated as if ophthalmopathy was not present. 8 As well as irradiating the thyroid gland therapeutic doses of radioiodine irradiate the gastrointestinal tract and, as radioiodine is excreted in the urine, the bladder and gonads (the gonadal dose is usually less than 30 mSv). This gives rise to concerns about possible long term effects such as carcinogenesis, teratogenesis, and infertility.
The question of carcinogenesis has been examined in most detail in the United States, where radioiodine has been given routinely for over 50 years. A few cases of thyroid cancer occurring in patients previously treated with radioiodine for thyrotoxicosis have been reported, although a review of 25 such cases suggested that they did not have the characteristics of radiation induced tumours (in particular a long latency from the time of radiation exposure, the mean latent period being only 7 3 years).9 In several other studies, with follow up data of more than 50 000 patient years, no relation was found between radioiodine treatment and the development of thyroid cancer. 10 Several large studies, with 400 000 years of patient follow up, have found no increased incidence of leukaemia" and no difference in the dose of radioiodine given to those who developed leukaemia and those who did not.'2 Likewise no firm evidence links radioiodine treatment with tumours at other sites, although a non-significant increase in breast cancer has been described after 30 years of observation.'3 These findings, together with recognition that long term follow up studies have included relatively few patients treated in adolescence (in whom no increased risk of malignancy has been identified'4), indicate the importance of collecting long term data.
Less direct information is available on the risks of congenital abnormality and infertility. Pregnancy is itself an absolute contraindication to radioiodine treatment; given inadvert-ently after the development of the fetal thyroid (10 weeks' gestation), radioiodine is associated with ablation of the thyroid, congenital hypothyroidism, and, in some cases, mental retardation. 5 None the less, if steps are taken to ensure that the patient is not pregnant at the time of treatment and avoids pregnancy for the next four months until the potential for fetal irradiation has disappeared there is no evidence for a significantly increased risk of congenital abnormality arising from gonadal irradiation.
The theoretically increased risk of genetic abnormality from radioiodine treatment in either sex has been estimated at 0-005%'6-unsurprisingly, such a risk has not been identified even in large studies. Much larger doses of radioiodine have been given to adolescents with thyroid cancer without abnormalities in offspring.'7 Reviews of the reproductive history of those receiving radioiodine for thyrotoxicosis, or larger doses for thyroid cancer, have also failed to show a subsequent risk of infertility.'4 Furthermore, patients irradiated during routine radiographic examinations receive similar gonadal doses to those receiving radioiodine therapeutically; such doses are considerably lower than those predicted to cause infertility,'8 so that this is not a concern in the treatment of thyrotoxicosis.
Despite the evidence that radioiodine is a safe treatment for thyrotoxicosis enthusiasm for its use differs between centres and countries. A recent survey found that one third of American doctors regarded radioiodine as the right treatment for a 19 year old woman presenting with moderately severe thyrotoxicosis; the corresponding European figure was 4%. 4 Since the age restrictions on the use of radioiodine were removed in Britain in 1983, all those with thyrotoxicosis in this country may now receive this treatment. Though it remains our general policy in Birmingham to treat -young patients at presentation with a 12 month course of antithyroid drugs and to proceed to radioiodine on relapse, we have found radioiodine increasingly useful in the initial management of young patients with thyrotoxicosis. Despite general concerns regarding the effects of radioactivity radioiodine is likely to become an increasingly popular treatment for thyrotoxicosis because of its safety, efficacy, and ease of administration. Euthanasia: time for a royal commission
The tide seems to be runningfor euthanasia It is time for the British to think deeply about euthanasia. The trial and conviction of rheumatologist Nigel Cox for attempted murder after giving a terminally ill patient a lethal injection has given the debate over euthanasia an almighty shove (p 731).1 The mood of the nation seems to be that the conviction may have been legally correct but that to destroy a caring doctor through such a trial was wrong: jurors burst into tears; the judge said that criminal trials could sometimes be an "overwhelming burden"; and the family wished that the trial had never happened. The law is in effect the codification of the will of the people, and when there is such tension between a legal verdict and the people's thinking then it is time to reconsider the law. A royal commission is the best way that the British have to examine such a difficult but universally important issue. Dr Cox's case may well prove to be a watershed. Euthanasia is rising up the agenda in many countries. In November 1991 the people of Washington state voted narrowly against a proposal to permit a "medical service provided in person by a physician, that will end the life of a conscious and mentally competent qualified patient in a dignified, painless and humane manner." As the BMJ's international round up earlier this year made clear,`' California and Oregon will hold similar referendums soon.2 In Britain the number of people agreeing with the statement "Some people say that the law should allow adults to receive medical help to an immediate peaceful death if they suffer from an incurable illness that is intolerable to them, provided that they have previously requested such help in writing" rose from 69% (95% confidence interval 67% to 71%) in 1976 to 75% in 1989 (73% to 77%) in 1989.3 Similar trends have been shown in Canada and Australia. 3 This slow but steady change in public opinion is reminiscent of what happened with abortion: in the past 30 years many countries have moved from extremely restrictive to liberal laws on abortion, and over the next 30 euthanasia may move from being covert to being legal. Dr Cox's case may then rank alongside those of doctors charged with procuring abortion in women who otherwise faced death from their pregnancies. In many countries suicide has been through the same passage from unacceptability to legality.
And not only the people are changing their views: politicians, bioethicists, and doctors are also changing. In Britain an all party group of members of parliament and peers has
